×
S&P 500   4,158.24 (+2.47%)
DOW   33,212.96 (+1.76%)
QQQ   309.10 (+3.26%)
AAPL   149.64 (+4.08%)
MSFT   273.24 (+2.76%)
FB   195.13 (+1.83%)
GOOGL   2,246.33 (+4.20%)
AMZN   2,302.93 (+3.66%)
TSLA   759.63 (+7.33%)
NVDA   188.11 (+5.38%)
BABA   93.41 (-1.13%)
NIO   16.57 (+3.37%)
AMD   102.26 (+3.55%)
CGC   4.88 (-12.07%)
MU   73.32 (+3.85%)
T   21.29 (-0.14%)
GE   78.76 (+2.27%)
F   13.63 (+3.89%)
DIS   109.32 (+3.51%)
AMC   14.43 (+17.99%)
PFE   53.91 (-0.15%)
PYPL   85.21 (+5.96%)
NFLX   195.19 (+1.98%)
S&P 500   4,158.24 (+2.47%)
DOW   33,212.96 (+1.76%)
QQQ   309.10 (+3.26%)
AAPL   149.64 (+4.08%)
MSFT   273.24 (+2.76%)
FB   195.13 (+1.83%)
GOOGL   2,246.33 (+4.20%)
AMZN   2,302.93 (+3.66%)
TSLA   759.63 (+7.33%)
NVDA   188.11 (+5.38%)
BABA   93.41 (-1.13%)
NIO   16.57 (+3.37%)
AMD   102.26 (+3.55%)
CGC   4.88 (-12.07%)
MU   73.32 (+3.85%)
T   21.29 (-0.14%)
GE   78.76 (+2.27%)
F   13.63 (+3.89%)
DIS   109.32 (+3.51%)
AMC   14.43 (+17.99%)
PFE   53.91 (-0.15%)
PYPL   85.21 (+5.96%)
NFLX   195.19 (+1.98%)
S&P 500   4,158.24 (+2.47%)
DOW   33,212.96 (+1.76%)
QQQ   309.10 (+3.26%)
AAPL   149.64 (+4.08%)
MSFT   273.24 (+2.76%)
FB   195.13 (+1.83%)
GOOGL   2,246.33 (+4.20%)
AMZN   2,302.93 (+3.66%)
TSLA   759.63 (+7.33%)
NVDA   188.11 (+5.38%)
BABA   93.41 (-1.13%)
NIO   16.57 (+3.37%)
AMD   102.26 (+3.55%)
CGC   4.88 (-12.07%)
MU   73.32 (+3.85%)
T   21.29 (-0.14%)
GE   78.76 (+2.27%)
F   13.63 (+3.89%)
DIS   109.32 (+3.51%)
AMC   14.43 (+17.99%)
PFE   53.91 (-0.15%)
PYPL   85.21 (+5.96%)
NFLX   195.19 (+1.98%)
S&P 500   4,158.24 (+2.47%)
DOW   33,212.96 (+1.76%)
QQQ   309.10 (+3.26%)
AAPL   149.64 (+4.08%)
MSFT   273.24 (+2.76%)
FB   195.13 (+1.83%)
GOOGL   2,246.33 (+4.20%)
AMZN   2,302.93 (+3.66%)
TSLA   759.63 (+7.33%)
NVDA   188.11 (+5.38%)
BABA   93.41 (-1.13%)
NIO   16.57 (+3.37%)
AMD   102.26 (+3.55%)
CGC   4.88 (-12.07%)
MU   73.32 (+3.85%)
T   21.29 (-0.14%)
GE   78.76 (+2.27%)
F   13.63 (+3.89%)
DIS   109.32 (+3.51%)
AMC   14.43 (+17.99%)
PFE   53.91 (-0.15%)
PYPL   85.21 (+5.96%)
NFLX   195.19 (+1.98%)
NYSE:BHVN

Biohaven Pharmaceutical (BHVN) Stock Forecast, Price & News

$143.37
+0.19 (+0.13%)
(As of 05/27/2022 12:00 AM ET)
Add
Compare
Today's Range
$143.05
$143.61
50-Day Range
$83.14
$143.40
52-Week Range
$79.01
$151.51
Volume
1.71 million shs
Average Volume
1.25 million shs
Market Capitalization
$10.11 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.2
30 days | 90 days | 365 days | Advanced Chart
Receive BHVN News and Ratings via Email

Sign-up to receive the latest news and ratings for Biohaven Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

Biohaven Pharmaceutical logo

About Biohaven Pharmaceutical

Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavegepant that is in phase III clinical trials for acute and preventive treatment of migraine, as well as respiratory complications and non-migraine studies; and BHV-3100 for non-migraine indications. The company also offers Troriluzole for spinocerebellar ataxia and obsessive compulsive disorders, as well as Alzheimer diseases; BHV-0223, a product for amyotrophic lateral sclerosis; BHV-5000/5500 for neuropsychiatric indications; and Verdiperstat, a product for multiple system atrophy and amyotrophic lateral sclerosis. Biohaven Pharmaceutical Holding Company Ltd. has a collaboration agreement with Cove to facilitate telemedicine evaluation for migraine sufferers. The company was incorporated in 2013 and is headquartered in New Haven, Connecticut.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Previous Symbol
NASDAQ:BHVN
Fax
N/A
Employees
928
Year Founded
N/A

Sales & Book Value

Annual Sales
$462.51 million
Book Value
($6.61) per share

Profitability

Net Income
$-846.59 million
Pretax Margin
-91.44%

Debt

Price-To-Earnings

Miscellaneous

Free Float
61,782,000
Market Cap
$10.11 billion
Optionable
Optionable

Company Calendar

Last Earnings
5/10/2022
Today
5/27/2022
Next Earnings (Estimated)
8/08/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

2.08 out of 5 stars

Medical Sector

494th out of 1,424 stocks

Pharmaceutical Preparations Industry

218th out of 681 stocks

Analyst Opinion: 2.2Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.6 5 -4 -3 -2 -1 -













Biohaven Pharmaceutical (NYSE:BHVN) Frequently Asked Questions

Is Biohaven Pharmaceutical a buy right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biohaven Pharmaceutical in the last year. There are currently 5 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Biohaven Pharmaceutical stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BHVN, but not buy additional shares or sell existing shares.
View analyst ratings for Biohaven Pharmaceutical
or view top-rated stocks.

Are investors shorting Biohaven Pharmaceutical?

Biohaven Pharmaceutical saw a drop in short interest during the month of May. As of May 15th, there was short interest totaling 4,130,000 shares, a drop of 16.2% from the April 30th total of 4,930,000 shares. Based on an average daily volume of 1,520,000 shares, the short-interest ratio is presently 2.7 days. Approximately 6.7% of the company's stock are short sold.
View Biohaven Pharmaceutical's Short Interest
.

When is Biohaven Pharmaceutical's next earnings date?

Biohaven Pharmaceutical is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022.
View our earnings forecast for Biohaven Pharmaceutical
.

How were Biohaven Pharmaceutical's earnings last quarter?

Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) issued its earnings results on Tuesday, May, 10th. The company reported ($2.97) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.52) by $0.45. During the same quarter in the previous year, the firm earned ($4.21) EPS.
View Biohaven Pharmaceutical's earnings history
.

What price target have analysts set for BHVN?

8 equities research analysts have issued twelve-month target prices for Biohaven Pharmaceutical's stock. Their forecasts range from $130.00 to $177.00. On average, they anticipate Biohaven Pharmaceutical's stock price to reach $155.11 in the next twelve months. This suggests a possible upside of 8.2% from the stock's current price.
View analysts' price targets for Biohaven Pharmaceutical
or view top-rated stocks among Wall Street analysts.

Who are Biohaven Pharmaceutical's key executives?
Biohaven Pharmaceutical's management team includes the following people:
  • Dr. Vladimir Coric M.D., Chairman, CEO & Pres (Age 51, Pay $1.81M)
  • Mr. Matthew Buten, Chief Financial Officer (Age 61, Pay $766.47k)
  • Ms. Kimberly Gentile, Sr. VP of Clinical Operations (Age 56, Pay $1.03M) (LinkedIn Profile)
  • Dr. Elyse Stock M.D., Chief Medical Officer (Age 63, Pay $1.15M)
  • Mr. William Jones M.B.A., Chief Commercial Officer of Migraine & Common Diseases (Age 58, Pay $1.04M)
  • Mr. Matthew DeLawder, Director of Accounting
  • Mr. George C. Clark, VP & Chief Accounting Officer (Age 38) (LinkedIn Profile)
  • Dr. Charles Conway Ph.D., Chief Scientific Officer (Age 60)
  • Ms. Wendy Goss, Exec. Admin. Assistant
  • Mr. Clifford Bechtold M.S., Pres & GM of Biohaven Ireland and Chief Compliance Officer
What other stocks do shareholders of Biohaven Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Biohaven Pharmaceutical investors own include AbbVie (ABBV), NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), Alibaba Group (BABA), ACADIA Pharmaceuticals (ACAD), QUALCOMM (QCOM), Pfizer (PFE), Sarepta Therapeutics (SRPT) and Abbott Laboratories (ABT).

When did Biohaven Pharmaceutical IPO?

(BHVN) raised $124 million in an initial public offering on Thursday, May 4th 2017. The company issued 8,300,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, Piper Jaffray and Barclays Capital served as the underwriters for the IPO and William Blair and Needham & Company were co-managers.

What is Biohaven Pharmaceutical's stock symbol?

Biohaven Pharmaceutical trades on the New York Stock Exchange (NYSE) under the ticker symbol "BHVN."

Who are Biohaven Pharmaceutical's major shareholders?

Biohaven Pharmaceutical's stock is owned by a variety of retail and institutional investors. Top institutional investors include Capital World Investors (9.42%), BlackRock Inc. (6.60%), Capital International Investors (3.80%), State Street Corp (2.35%), Vanguard Group Inc. (2.02%) and JPMorgan Chase & Co. (1.94%). Company insiders that own Biohaven Pharmaceutical stock include Declan Doogan, Elyse Stock, George C Clark, Gregory Bailey, James Engelhart, John Tilton, John W Childs, Julia P Gregory, Kimberly Gentile, Robert Berman and William A Jones Jr.
View institutional ownership trends for Biohaven Pharmaceutical
.

Which major investors are selling Biohaven Pharmaceutical stock?

BHVN stock was sold by a variety of institutional investors in the last quarter, including Capital International Investors, Gilder Gagnon Howe & Co. LLC, Invesco Ltd., Hood River Capital Management LLC, EULAV Asset Management, Northern Trust Corp, Nicholas Investment Partners LP, and Pier Capital LLC. Company insiders that have sold Biohaven Pharmaceutical company stock in the last year include Declan Doogan, Elyse Stock, George C Clark, James Engelhart, and Julia P Gregory.
View insider buying and selling activity for Biohaven Pharmaceutical
or view top insider-selling stocks.

Which major investors are buying Biohaven Pharmaceutical stock?

BHVN stock was purchased by a variety of institutional investors in the last quarter, including Viking Global Investors LP, American Century Companies Inc., Capital World Investors, Eversept Partners LP, Clearbridge Investments LLC, Fairmount Funds Management LLC, Lord Abbett & CO. LLC, and Goldman Sachs Group Inc..
View insider buying and selling activity for Biohaven Pharmaceutical
or or view top insider-buying stocks.

How do I buy shares of Biohaven Pharmaceutical?

Shares of BHVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Biohaven Pharmaceutical's stock price today?

One share of BHVN stock can currently be purchased for approximately $143.37.

How much money does Biohaven Pharmaceutical make?

Biohaven Pharmaceutical has a market capitalization of $10.11 billion and generates $462.51 million in revenue each year. The company earns $-846.59 million in net income (profit) each year or ($11.840010) on an earnings per share basis.

How many employees does Biohaven Pharmaceutical have?

Biohaven Pharmaceutical employs 928 workers across the globe.

What is Biohaven Pharmaceutical's official website?

The official website for Biohaven Pharmaceutical is www.biohavenpharma.com.

How can I contact Biohaven Pharmaceutical?

Biohaven Pharmaceutical's mailing address is 215 CHURCH STREET, NEW HAVEN CT, 06510. The company can be reached via phone at (203) 404-0410 or via email at [email protected].

This page was last updated on 5/27/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.